Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Launching Pelvic Mass Registry With $7.5M From CPRIT

NEW YORK (GenomeWeb) – Vermillion said today that it has formed a steering committee for a Pelvic Mass Registry it is developing with $7.5 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT).

The company aims to enroll 3,000 women in the registry which it plans to use for research and development of diagnostics and other tests for the early detection, differential diagnosis, and treatment of pelvic masses. Through analysis of these patients, it hopes to identify analytes including proteins and nucleic acids as well as measures based on imaging and clinical factors that can be used for detection and management of gynecologic diseases.

"By sifting patient data and clinical samples for innovative diagnostic patterns, we hope to re-engineer the methods physicians use to sort and treat these conditions, Judith Wolf, Vermillion's chief medical officer and registry co-primary investigator, said in a statement.

The registry steering committee will advise Vermillion on scientific and clinical strategies and oversee study design and publication. Its members include experts on ovarian cancer, endometriosis, and public health policy.

The CPRIT grant is subject to completion of a contract between Vermillion and the institute and may include terms such as payment of future product royalties to CPRIT by Vermillion.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.